Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Febuxostat - Teijin Pharma

Drug Profile

Febuxostat - Teijin Pharma

Alternative Names: Adenuric; Feburic; Febuxostat XR; TEI-6720; TMX 67XR; TMX-67; Uloric

Latest Information Update: 04 Nov 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Teijin Pharma
  • Developer Astellas Pharma; Ipsen; Menarini; SK Chemicals; Takeda Pharmaceuticals USA; Teijin Pharma
  • Class Antigouts; Antihypertensives; Carboxylic acids; Nitriles; Phenyl ethers; Small molecules; Thiazoles
  • Mechanism of Action Xanthine oxidase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Hyperuricaemia
  • Registered Tumour lysis syndrome
  • Phase II Hypertension
  • Suspended Angina pectoris

Most Recent Events

  • 10 Sep 2018 Teijin Pharma completes the phase II FEATHER trial for Hyperuricaemia (in patients with gout) in Japan (PO) (UMIN000008343)
  • 07 Sep 2018 The Ministry of Health, Labour and Welfare, Japan issues a notification on the extension of the reexamination period for the treatment of hyperuricaemia and gout
  • 01 Sep 2018 Teijin pharma initiates enrolment in a phase II trial for Hyperuricema (In Children) in Japan (JapicCTI-184136)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top